Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma
To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC). This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine J...
Gespeichert in:
Veröffentlicht in: | Pakistan journal of medical sciences 2024-09, Vol.40 (8), p.1663 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 8 |
container_start_page | 1663 |
container_title | Pakistan journal of medical sciences |
container_volume | 40 |
creator | Wang, Xiao Zhang, Dan Li, Kang Guo, Peng Lei, Zhi-Xiong |
description | To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC).
This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine January 2019 and June 2021 were included. The patients were divided into the control group and the experimental group according to their treatment regimens. The control group received TACE treatment, while the experimental group received TACE combined with targeted therapy. We analyze the relevant data of two groups of patients and evaluate the clinical efficacy and safety of TACE combined with targeted therapy.
The tumor remission rate and control rate in the control group were 41.89% and 75.68%, respectively, while those in the experimental group were 77.63% and 90.79%, with statistically significant differences (p |
doi_str_mv | 10.12669/pjms.40.8.8982 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3106039162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A807377868</galeid><sourcerecordid>A807377868</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-1bfe5301d684527e9166800662514787d1fa9315d7f4be012637f709f3ab207e3</originalsourceid><addsrcrecordid>eNptksFrFDEUxgdRbK2evUlAEC8zTSYzSeZYlqqFggdX6C1kMi-dLDPJmmSQ9eo_bqbdqhXJ4SXh9z7e-_iK4jXBFakZ6873uzlWDa5EJTpRPylOCROk5KS9eXp3r0tcNzcnxYsYdxg3rGnr58UJ7WpB6lacFj83k3VWqwldGpOrPiDlBvRFGUgH5A1KQbmoQoJgM6RHmD3MvZ_sD5Wsd2jj5946GNB3m0a0VeEWUn5tRwhqf0DGB7QPdlbhgEbYq-Q1TNMyqYC0Cto6P6uXxTOjpgivjvWs-Prhcrv5VF5__ni1ubgudUNEKklvoKWYDEzkLTh0hDGBMWN1Sxou-ECM6ihpB26aHnD2h3LDcWeo6mvMgZ4V7-9198F_WyAmOdu4jqMc-CVKSjDDNMvWGX37D7rzS3B5upXCHcac8T_UrZpAWmd8dkuvovJCYE45F0xkqvoPlc8As9XegbH5_1HDu78aRlBTGqOfltXv-Bg8vwd18DEGMPJotSRY3uVDrvmQDZZCrvnIHW-Oey39DMNv_iEQ9Be2ybW_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3100900767</pqid></control><display><type>article</type><title>Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Wang, Xiao ; Zhang, Dan ; Li, Kang ; Guo, Peng ; Lei, Zhi-Xiong</creator><creatorcontrib>Wang, Xiao ; Zhang, Dan ; Li, Kang ; Guo, Peng ; Lei, Zhi-Xiong</creatorcontrib><description>To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC).
This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine January 2019 and June 2021 were included. The patients were divided into the control group and the experimental group according to their treatment regimens. The control group received TACE treatment, while the experimental group received TACE combined with targeted therapy. We analyze the relevant data of two groups of patients and evaluate the clinical efficacy and safety of TACE combined with targeted therapy.
The tumor remission rate and control rate in the control group were 41.89% and 75.68%, respectively, while those in the experimental group were 77.63% and 90.79%, with statistically significant differences (p<0.05). The 1-year and 3-year recurrence rates in the control group were 52.71% and 98.65%, respectively, while those in the experimental group were 39.47% and 61.84%, with statistically significant differences (p<0.05). After treatment, the AFP, VEGF, ALT, and AST in the experimental group were significantly reduced compared to the control group (p<0.05). During the treatment period, the incidence and severity of nausea, vomiting, and fever in the experimental group were significantly lower than those in the control group (p<0.05).
The clinical efficacy of TACE combined with targeted therapy for PHC is superior to that of TACE alone, with improved disease control rate, improved long-term survival rate, and good safety.</description><identifier>ISSN: 1682-024X</identifier><identifier>EISSN: 1681-715X</identifier><identifier>DOI: 10.12669/pjms.40.8.8982</identifier><identifier>PMID: 39281258</identifier><language>eng</language><publisher>Pakistan: Knowledge Bylanes</publisher><subject>Cholangiocarcinoma ; Diarrhea ; Fever ; Health aspects ; Hepatoma ; Hospitals ; Liver ; Liver cancer ; Medical colleges ; Medical prognosis ; Mortality ; Nausea ; Tumors ; Vascular endothelial growth factor</subject><ispartof>Pakistan journal of medical sciences, 2024-09, Vol.40 (8), p.1663</ispartof><rights>Copyright: © Pakistan Journal of Medical Sciences.</rights><rights>COPYRIGHT 2024 Knowledge Bylanes</rights><rights>(c)2024 Pakistan Journal of Medical Sciences</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39281258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Xiao</creatorcontrib><creatorcontrib>Zhang, Dan</creatorcontrib><creatorcontrib>Li, Kang</creatorcontrib><creatorcontrib>Guo, Peng</creatorcontrib><creatorcontrib>Lei, Zhi-Xiong</creatorcontrib><title>Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma</title><title>Pakistan journal of medical sciences</title><addtitle>Pak J Med Sci</addtitle><description>To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC).
This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine January 2019 and June 2021 were included. The patients were divided into the control group and the experimental group according to their treatment regimens. The control group received TACE treatment, while the experimental group received TACE combined with targeted therapy. We analyze the relevant data of two groups of patients and evaluate the clinical efficacy and safety of TACE combined with targeted therapy.
The tumor remission rate and control rate in the control group were 41.89% and 75.68%, respectively, while those in the experimental group were 77.63% and 90.79%, with statistically significant differences (p<0.05). The 1-year and 3-year recurrence rates in the control group were 52.71% and 98.65%, respectively, while those in the experimental group were 39.47% and 61.84%, with statistically significant differences (p<0.05). After treatment, the AFP, VEGF, ALT, and AST in the experimental group were significantly reduced compared to the control group (p<0.05). During the treatment period, the incidence and severity of nausea, vomiting, and fever in the experimental group were significantly lower than those in the control group (p<0.05).
The clinical efficacy of TACE combined with targeted therapy for PHC is superior to that of TACE alone, with improved disease control rate, improved long-term survival rate, and good safety.</description><subject>Cholangiocarcinoma</subject><subject>Diarrhea</subject><subject>Fever</subject><subject>Health aspects</subject><subject>Hepatoma</subject><subject>Hospitals</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Medical colleges</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Nausea</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>1682-024X</issn><issn>1681-715X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptksFrFDEUxgdRbK2evUlAEC8zTSYzSeZYlqqFggdX6C1kMi-dLDPJmmSQ9eo_bqbdqhXJ4SXh9z7e-_iK4jXBFakZ6873uzlWDa5EJTpRPylOCROk5KS9eXp3r0tcNzcnxYsYdxg3rGnr58UJ7WpB6lacFj83k3VWqwldGpOrPiDlBvRFGUgH5A1KQbmoQoJgM6RHmD3MvZ_sD5Wsd2jj5946GNB3m0a0VeEWUn5tRwhqf0DGB7QPdlbhgEbYq-Q1TNMyqYC0Cto6P6uXxTOjpgivjvWs-Prhcrv5VF5__ni1ubgudUNEKklvoKWYDEzkLTh0hDGBMWN1Sxou-ECM6ihpB26aHnD2h3LDcWeo6mvMgZ4V7-9198F_WyAmOdu4jqMc-CVKSjDDNMvWGX37D7rzS3B5upXCHcac8T_UrZpAWmd8dkuvovJCYE45F0xkqvoPlc8As9XegbH5_1HDu78aRlBTGqOfltXv-Bg8vwd18DEGMPJotSRY3uVDrvmQDZZCrvnIHW-Oey39DMNv_iEQ9Be2ybW_</recordid><startdate>20240930</startdate><enddate>20240930</enddate><creator>Wang, Xiao</creator><creator>Zhang, Dan</creator><creator>Li, Kang</creator><creator>Guo, Peng</creator><creator>Lei, Zhi-Xiong</creator><general>Knowledge Bylanes</general><general>AsiaNet Pakistan (Pvt) Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20240930</creationdate><title>Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma</title><author>Wang, Xiao ; Zhang, Dan ; Li, Kang ; Guo, Peng ; Lei, Zhi-Xiong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-1bfe5301d684527e9166800662514787d1fa9315d7f4be012637f709f3ab207e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cholangiocarcinoma</topic><topic>Diarrhea</topic><topic>Fever</topic><topic>Health aspects</topic><topic>Hepatoma</topic><topic>Hospitals</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Medical colleges</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Nausea</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xiao</creatorcontrib><creatorcontrib>Zhang, Dan</creatorcontrib><creatorcontrib>Li, Kang</creatorcontrib><creatorcontrib>Guo, Peng</creatorcontrib><creatorcontrib>Lei, Zhi-Xiong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pakistan journal of medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xiao</au><au>Zhang, Dan</au><au>Li, Kang</au><au>Guo, Peng</au><au>Lei, Zhi-Xiong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma</atitle><jtitle>Pakistan journal of medical sciences</jtitle><addtitle>Pak J Med Sci</addtitle><date>2024-09-30</date><risdate>2024</risdate><volume>40</volume><issue>8</issue><spage>1663</spage><pages>1663-</pages><issn>1682-024X</issn><eissn>1681-715X</eissn><abstract>To explore the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with targeted therapy for primary hepatocellular carcinoma (PHC).
This was a retrospective study. Retrospective selection of 150 PHC patients admitted to the Renmin Hospital, Hubei University of Medicine January 2019 and June 2021 were included. The patients were divided into the control group and the experimental group according to their treatment regimens. The control group received TACE treatment, while the experimental group received TACE combined with targeted therapy. We analyze the relevant data of two groups of patients and evaluate the clinical efficacy and safety of TACE combined with targeted therapy.
The tumor remission rate and control rate in the control group were 41.89% and 75.68%, respectively, while those in the experimental group were 77.63% and 90.79%, with statistically significant differences (p<0.05). The 1-year and 3-year recurrence rates in the control group were 52.71% and 98.65%, respectively, while those in the experimental group were 39.47% and 61.84%, with statistically significant differences (p<0.05). After treatment, the AFP, VEGF, ALT, and AST in the experimental group were significantly reduced compared to the control group (p<0.05). During the treatment period, the incidence and severity of nausea, vomiting, and fever in the experimental group were significantly lower than those in the control group (p<0.05).
The clinical efficacy of TACE combined with targeted therapy for PHC is superior to that of TACE alone, with improved disease control rate, improved long-term survival rate, and good safety.</abstract><cop>Pakistan</cop><pub>Knowledge Bylanes</pub><pmid>39281258</pmid><doi>10.12669/pjms.40.8.8982</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1682-024X |
ispartof | Pakistan journal of medical sciences, 2024-09, Vol.40 (8), p.1663 |
issn | 1682-024X 1681-715X |
language | eng |
recordid | cdi_proquest_miscellaneous_3106039162 |
source | DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
subjects | Cholangiocarcinoma Diarrhea Fever Health aspects Hepatoma Hospitals Liver Liver cancer Medical colleges Medical prognosis Mortality Nausea Tumors Vascular endothelial growth factor |
title | Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T13%3A24%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Efficacy%20and%20Safety%20of%20transarterial%20chemoembolization%20Combined%20with%20Targeted%20Therapy%20for%20primary%20hepatocellular%20carcinoma&rft.jtitle=Pakistan%20journal%20of%20medical%20sciences&rft.au=Wang,%20Xiao&rft.date=2024-09-30&rft.volume=40&rft.issue=8&rft.spage=1663&rft.pages=1663-&rft.issn=1682-024X&rft.eissn=1681-715X&rft_id=info:doi/10.12669/pjms.40.8.8982&rft_dat=%3Cgale_proqu%3EA807377868%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3100900767&rft_id=info:pmid/39281258&rft_galeid=A807377868&rfr_iscdi=true |